High-Throughput Gene-Editing via Microfluidic Cell Deformability to Enable Off-the-Shelf Allogeneic Cellular Immunotherapies |
University of California, Los Angeles / Steven Jonas, MD/PhD |
Young Investigator Grants |
2017 |
California |
Targeting Chondroitin Sulphate Proteoglycan 4 (CSPG4) in Glioblastoma |
University of North Carolina / Gianpietro Dotti, MD & Barbara Savoldo, MD/PhD |
Reach Grants |
2017 |
North Carolina |
Understanding the Mechanisms of HOX Gene Regulation in Normal and Leukemic Hematopoietic Stem Cells to Identify New Therapies for Pediatric AML |
Boston Children’s Hospital / Anne Robertson, PhD |
Young Investigator Grants |
2017 |
Massachusetts |
Role of N6-Methyladenosine (m6A) mRNA Modification Pathway in Neuroblastoma |
Boston Children’s Hospital / Shuibin Lin, PhD |
Young Investigator Grants |
2017 |
Massachusetts |
Phase I Study of Lentivirus Engineered Autologous AML Cells Expressing IL-12 in Children and Young Adults with Relapsed AML |
Children’s Hospital of Wisconsin - Milwaukee / Michael Burke, MD & Jeffrey Medin, MD/PhD |
Reach Grants |
2017 |
Wisconsin |
End-of-Life Care of Children with Cancer: Variation and Stakeholder Priorities |
University of Alabama at Birmingham / Emily Johnston, MD |
Young Investigator Grants |
2017 |
Alabama |
Development of Novel Biomarkers for Immunotherapy in Neuroblastoma |
Columbia Institute for Cancer Genetics / Shuobo Boboila, PhD |
Young Investigator Grants |
2017 |
New York |
Cancer Susceptibility and Signaling Pathways in Low-Grade Brain Tumors |
Jewish General Hospital / Bárbara Rivera, PhD |
Young Investigator Grants |
2017 |
Quebec |
Role of Protocadherin-9 in Enabling Leukemia Cell Colonization of the CNS |
National Jewish Health / Jordan Jacobelli, PhD |
Innovation Grants |
2017 |
Colorado |
Characterization of Novel OTX2-semaphorin Gene Signaling Pathways Regulating the ‘Grow and Go’ Arms of Highly Aggressive Medulloblastomas |
University of Manitoba / Tamra Werbowetski-Ogilvie, PhD |
Innovation Grants |
2017 |
Manitoba |